Verve Therapeutics (VERV)
US Market

Verve Therapeutics (VERV) Stock Price & Analysis


VERV Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$10.70 - $43.00
Previous Close$22.42
Average Volume (3M)959.89K
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$550.71M
Total Debt (Recent Filing)$79.92M
Price to Earnings (P/E)-7.7
Next EarningsMar 13, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
EPS (TTM)-2.90
Shares Outstanding61,603,788
Standard Deviation0.28
10 Day Avg. Volume615,516
30 Day Avg. Volume959,886
Price to Book (P/B)2.34
Price to Sales (P/S)1431.67
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-13.10
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Price Target Upside28.59% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5



Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Verve Therapeutics’s price range in the past 12 months?
Verve Therapeutics lowest stock price was $10.70 and its highest was $43.00 in the past 12 months.
    What is Verve Therapeutics’s market cap?
    Currently, no data Available
    When is Verve Therapeutics’s upcoming earnings report date?
    Verve Therapeutics’s upcoming earnings report date is Mar 13, 2023 which is in 42 days.
      How were Verve Therapeutics’s earnings last quarter?
      Verve Therapeutics released its earnings results on Nov 07, 2022. The company reported -$0.79 earnings per share for the quarter, missing the consensus estimate of -$0.742 by -$0.048.
        Is Verve Therapeutics overvalued?
        According to Wall Street analysts Verve Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Verve Therapeutics pay dividends?
          Verve Therapeutics does not currently pay dividends.
          What is Verve Therapeutics’s EPS estimate?
          Verve Therapeutics’s EPS estimate is -$0.76.
            How many shares outstanding does Verve Therapeutics have?
            Verve Therapeutics has 61,603,786 shares outstanding.
              What happened to Verve Therapeutics’s price movement after its last earnings report?
              Verve Therapeutics reported an EPS of -$0.79 in its last earnings report, missing expectations of -$0.742. Following the earnings report the stock price went down -30.489%.
                Which hedge fund is a major shareholder of Verve Therapeutics?
                Among the largest hedge funds holding Verve Therapeutics’s share is ARK Investment Management LLC. It holds Verve Therapeutics’s shares valued at 117M.


                  Verve Therapeutics Stock Smart Score

                  The Verve Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Verve Therapeutics

                  Verve Therapeutics Inc is a genetic medicines company pioneering the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. Its initial programs focus on PCSK9 and ANGPTL3, two genes that regulate levels of blood lipids. The company is developing these gene-editing treatments for patients with familial hypercholesterolemia, a genetic disease that causes life-long severely elevated blood cholesterol.


                  Forecast EPS vs Actual EPS

                  Similar Stocks
                  Price & Change
                  Rhythm Pharmaceuticals
                  Twist Bioscience
                  Rocket Pharmaceuticals
                  Allogene Therapeutics
                  Springworks Therapeutics

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis